We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+89.28%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$499M
AUM Growth
+$188M
Cap. Flow
+$206M
Cap. Flow %
41.36%
Top 10 Hldgs %
50.9%
Holding
101
New
48
Increased
19
Reduced
18
Closed
14

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$44.5M
2
DNLI icon
Denali Therapeutics
DNLI
+$14.8M
3
BHVN icon
Biohaven
BHVN
+$12.3M
4
WVE icon
Wave Life Sciences
WVE
+$9.79M
5
ARGX icon
argenx
ARGX
+$8.22M

Top Sells

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$16.6M
2
MRUS
Merus
MRUS
+$14M
3
ACLX
Arcellx
ACLX
+$13.7M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$13.2M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.58%
2 Financials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ROIV icon
1
Roivant Sciences
ROIV
$24.8B
$63.5M 12.72%
4,197,187
+3,595,406
+597% +$44.5M
QURE icon
2
uniQure
QURE
$2.77B
$30.5M 6.11%
522,155
-50,460
-9% -$916K
SRRK icon
3
Scholar Rock
SRRK
$6.33B
$27M 5.42%
726,204
+198,089
+38% +$6.93M
IMVT icon
4
Immunovant
IMVT
$8.27B
$25.6M 5.13%
1,589,580
+288,720
+22% +$4.67M
DNLI icon
5
Denali Therapeutics
DNLI
$3.7B
$25.2M 5.05%
1,734,659
+1,026,744
+145% +$14.8M
SNDX icon
6
Syndax Pharmaceuticals
SNDX
$2.02B
$21M 4.21%
1,366,205
-1,006,429
-42% -$13.2M
CNTA
7
DELISTED
Centessa Pharmaceuticals
CNTA
$15.9M 3.18%
655,385
-610,287
-48% -$10.8M
WVE icon
8
Wave Life Sciences
WVE
$1.12B
$15.4M 3.09%
2,110,152
+1,209,814
+134% +$9.79M
BHVN icon
9
Biohaven
BHVN
$2.32B
$15.3M 3.06%
1,017,311
+842,557
+482% +$12.3M
CDTX
10
DELISTED
Cidara Therapeutics
CDTX
$14.6M 2.92%
152,325
-114,449
-43% -$7.3M
ABVX
11
Abivax
ABVX
$11.9B
$14.1M 2.83%
166,273
+78,525
+89% +$4.81M
IDYA icon
12
IDEAYA Biosciences
IDYA
$3.47B
$10.1M 2.03%
371,825
+205,940
+124% +$4.98M
RYTM icon
13
Rhythm Pharmaceuticals
RYTM
$7.31B
$9.23M 1.85%
91,444
-85,308
-48% -$7.92M
ARGX icon
14
argenx
ARGX
$53.8B
$9.19M 1.84%
+12,465
New +$8.22M
SRZN icon
15
Surrozen
SRZN
$255M
$9.19M 1.84%
713,463
+26,924
+4% +$282K
RVMD icon
16
Revolution Medicines
RVMD
$39.6B
$8.66M 1.73%
+185,380
New +$7.26M
RZLT icon
17
Rezolute
RZLT
$444M
$8.63M 1.73%
917,630
+272,976
+42% +$1.82M
GHRS icon
18
GH Research
GHRS
$1.97B
$7.8M 1.56%
545,275
+444,449
+441% +$6.22M
ARQT icon
19
Arcutis Biotherapeutics
ARQT
$3.56B
$7.76M 1.56%
411,893
+206,221
+100% +$3.25M
VTGN icon
20
VistaGen Therapeutics
VTGN
$9.4M
$7.75M 1.55%
2,488,685
+75,431
+3% +$225K
XENE icon
21
Xenon Pharmaceuticals
XENE
$6.6B
$7.72M 1.55%
+192,295
New +$6.77M
ALKS icon
22
Alkermes
ALKS
$8.79B
$7.25M 1.45%
241,637
-109,487
-31% -$3.09M
CELC icon
23
Celcuity
CELC
$4.31B
$6.75M 1.35%
+136,710
New +$5.47M
BBIO icon
24
BridgeBio Pharma
BBIO
$15.9B
$6.62M 1.33%
127,435
+72,805
+133% +$3.55M
INSM icon
25
Insmed
INSM
$23.5B
$6.25M 1.25%
43,419
-18,159
-29% -$2.22M
1
2 3 4 5

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Stempoint Capital held 101 positions worth $499M, up 60% from $312M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Stempoint Capital deployed $206M of net new capital in Q3 2025, opening 48 new positions and adding to 19 existing holdings. Its largest new stake was argenx: 12,465 shares worth $9.19M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Madrigal Pharmaceuticals, an estimated $16.6M trimmed.

  • Stempoint Capital's largest Q3 2025 buy was argenx: 12,465 shares worth $9.19M.
  • Stempoint Capital added most to Roivant Sciences in Q3 2025, an estimated $44.5M increase.
  • Stempoint Capital's biggest Q3 2025 reduction was Madrigal Pharmaceuticals, cutting an estimated $16.6M.
  • Stempoint Capital fully exited Merus in Q3 2025, selling an estimated $14M.
  • Stempoint Capital's ten largest holdings make up 51% of its $499M portfolio in Q3 2025.
  • Stempoint Capital opened 48 new positions and closed 14 in Q3 2025.
  • Stempoint Capital's portfolio value rose 60% quarter-over-quarter to $499M.

Based on Stempoint Capital's 13F filing for Q3 2025, filed 14 Nov 2025.